ATE549035T1 - Neue formen von cddo-methylester - Google Patents

Neue formen von cddo-methylester

Info

Publication number
ATE549035T1
ATE549035T1 AT08795303T AT08795303T ATE549035T1 AT E549035 T1 ATE549035 T1 AT E549035T1 AT 08795303 T AT08795303 T AT 08795303T AT 08795303 T AT08795303 T AT 08795303T AT E549035 T1 ATE549035 T1 AT E549035T1
Authority
AT
Austria
Prior art keywords
methyl ester
new forms
cddo methyl
cddo
new
Prior art date
Application number
AT08795303T
Other languages
English (en)
Inventor
John Walling
Stephan Parent
David Jonaitis
Robert Kral
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE549035T1 publication Critical patent/ATE549035T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)
AT08795303T 2007-08-15 2008-08-14 Neue formen von cddo-methylester ATE549035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95593907P 2007-08-15 2007-08-15
PCT/US2008/009703 WO2009023232A1 (en) 2007-08-15 2008-08-14 Novel forms of cddo methyl ester

Publications (1)

Publication Number Publication Date
ATE549035T1 true ATE549035T1 (de) 2012-03-15

Family

ID=40351005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08795303T ATE549035T1 (de) 2007-08-15 2008-08-14 Neue formen von cddo-methylester

Country Status (28)

Country Link
US (3) US8088824B2 (de)
EP (2) EP2187741B1 (de)
JP (4) JP5005812B2 (de)
KR (2) KR101544766B1 (de)
CN (2) CN101820758B (de)
AR (2) AR073155A1 (de)
AT (1) ATE549035T1 (de)
AU (1) AU2008287388B2 (de)
BR (1) BRPI0815540A8 (de)
CA (2) CA2696330C (de)
CL (1) CL2008002417A1 (de)
CY (2) CY1112864T1 (de)
DK (2) DK2187741T3 (de)
EA (2) EA018704B1 (de)
ES (2) ES2382571T3 (de)
HR (2) HRP20120350T1 (de)
HU (1) HUE031866T2 (de)
IL (2) IL203824A (de)
LT (1) LT2450057T (de)
MX (1) MX2010001628A (de)
NZ (1) NZ583269A (de)
PL (2) PL2450057T3 (de)
PT (2) PT2187741E (de)
SG (2) SG10201504650VA (de)
SI (2) SI2450057T1 (de)
TW (2) TWI486357B (de)
WO (1) WO2009023232A1 (de)
ZA (1) ZA201001066B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
DK1465615T3 (da) 2002-01-15 2012-11-12 Dartmouth College Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2094651A1 (de) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthese und biologische wirkungen neuer tricyclischer bis-enone (tbes)
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
ME03529B (de) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Synthetische triterpenoide und anwendungsverfahren bei der behandlung von erkrankungen
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
RS58392B1 (sr) * 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
EP2279197B1 (de) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidationsmittel als entzündungsmodulierende substanz: im c-ring gesättigte oleanolsäurederivate
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
SG173601A1 (en) * 2009-02-13 2011-09-29 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
CA2789950C (en) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
ES2653717T3 (es) 2010-12-17 2018-02-08 Reata Pharmaceuticals, Inc. Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación
EA026847B1 (ru) 2011-03-11 2017-05-31 Рита Фармасьютикалз, Инк. C4-монометилтритерпеноидные производные и способы их применения
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
EP2841445B1 (de) 2012-04-27 2017-06-14 Reata Pharmaceuticals, Inc. 2,2-difluorpropionamidderivate von bardoxolonmethyl, polymorphe formen davon und verfahren zur verwendung davon
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
TWI630212B (zh) 2012-09-10 2018-07-21 瑞塔醫藥有限責任公司 丁香油素(oleanolic acid)之c17-烷二基與烯二基衍生物及其使用方法
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es) * 2012-09-10 2015-11-09 Abbvie Inc Derivados de acido glicirretinico y metodos de uso de los mismos.
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CA2813934C (en) 2012-09-28 2016-12-13 Applied Pharmaceutical Science, Inc. Polymorphs of cddo ethyl ester and uses thereof
CN102875634B (zh) * 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
EP2977381B1 (de) 2013-03-19 2018-09-26 Daiichi Sankyo Company, Limited Terpenoidderivat
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US9896475B2 (en) 2014-08-26 2018-02-20 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
EP3192875B1 (de) 2014-09-10 2019-12-18 Daiichi Sankyo Company, Limited Pharmazeutische retard-zusammensetzung zur behandlung und vorbeugung von augenerkrankungen
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
SMT202200091T1 (it) 2014-12-19 2022-03-21 Geistlich Pharma Ag Processi per preparare composti simili a ossatiazina
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
AU2016219109B2 (en) 2015-02-12 2020-05-14 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
BR112018005861B1 (pt) 2015-09-23 2022-11-22 Reata Pharmaceuticals, Inc Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals, Inc. métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
EP3773509B1 (de) 2018-04-06 2023-11-01 Capsugel Belgium NV Sprühtrocknungsverfahren für teilchen mit niedrigem aspektverhältnis mit poly[(methyl-methacrylat)-co-(methacrylsäure)]
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
WO2020111089A1 (ja) 2018-11-27 2020-06-04 協和キリン株式会社 医薬組成物
CN120248001A (zh) 2019-07-19 2025-07-04 里亚塔医药公司 C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
CA3177913A1 (en) 2020-05-09 2021-11-18 Deborah FERGUSON Methods of treating covid-19 using bardoxolone methyl or analogs thereof
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US20240293351A1 (en) 2020-12-11 2024-09-05 Reata Pharmaceuticals Holdings, LLC Methods of administering synthetic triterpenoids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07121911B2 (ja) * 1986-03-26 1995-12-25 クミアイ化学工業株式会社 4(1h)−ピリジノン誘導体および農園芸用殺菌剤
JPH01273020A (ja) * 1988-04-26 1989-10-31 Toray Ind Inc 有機非線形光学材料
US5064823A (en) * 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP2876144B2 (ja) * 1990-03-23 1999-03-31 東洋フアルマー株式会社 3―フェニルクマリン―7―イルオキシ酢酸誘導体とその製法及び用途
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002047611A2 (en) * 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
EP1507541A4 (de) * 2002-05-13 2009-06-03 Dartmouth College Hemmer und anwendungsverfahren dafür
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
CN100419534C (zh) 2003-12-08 2008-09-17 索尼株式会社 液晶显示设备和背光调节方法
US20060167097A1 (en) * 2004-04-16 2006-07-27 Cheppail Ramachandran Compositions and uses of Amooranin compounds
EP2270000B1 (de) * 2005-05-23 2015-07-29 Novartis AG Kristalline und andere Formen von 4-Amino-5-Fluor-3-[6-(Methylpiperazin-1-yl)-1H-Benzimidazol-2-yl]-1H-Chinolin-2-on-Milchsäuresalz
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester

Also Published As

Publication number Publication date
NZ583269A (en) 2012-03-30
EP2187741A4 (de) 2010-08-25
HK1143537A1 (en) 2011-01-07
KR101481764B1 (ko) 2015-01-13
AR073155A1 (es) 2010-10-20
EP2187741A1 (de) 2010-05-26
KR101544766B1 (ko) 2015-08-17
KR20100056488A (ko) 2010-05-27
EA201370109A1 (ru) 2014-01-30
US20120330050A1 (en) 2012-12-27
HRP20161503T1 (hr) 2017-01-13
SI2187741T1 (sl) 2012-07-31
SG177905A1 (en) 2012-02-28
EA201070149A1 (ru) 2010-08-30
JP2015164939A (ja) 2015-09-17
JP2012188438A (ja) 2012-10-04
TWI486357B (zh) 2015-06-01
ZA201001066B (en) 2010-10-27
EA023550B1 (ru) 2016-06-30
DK2187741T3 (da) 2012-04-16
CY1112864T1 (el) 2016-04-13
BRPI0815540A2 (pt) 2014-09-30
JP2018009001A (ja) 2018-01-18
CA2696330A1 (en) 2009-02-19
WO2009023232A1 (en) 2009-02-19
US8633243B2 (en) 2014-01-21
PT2187741E (pt) 2012-06-21
CA2696330C (en) 2015-03-24
CA2871864C (en) 2016-05-17
DK2450057T3 (en) 2016-12-19
US8088824B2 (en) 2012-01-03
PL2450057T3 (pl) 2017-02-28
CN103254267B (zh) 2016-03-16
JP5005812B2 (ja) 2012-08-22
TW201402597A (zh) 2014-01-16
BRPI0815540A8 (pt) 2023-04-11
TW200916476A (en) 2009-04-16
SG10201504650VA (en) 2015-07-30
US8309601B2 (en) 2012-11-13
ES2602978T3 (es) 2017-02-23
IL251419A0 (en) 2017-05-29
EP2450057A1 (de) 2012-05-09
PL2187741T3 (pl) 2012-08-31
PT2450057T (pt) 2016-12-15
HUE031866T2 (en) 2017-08-28
CY1118329T1 (el) 2017-06-28
MX2010001628A (es) 2010-06-02
CN101820758B (zh) 2013-03-06
KR20140024063A (ko) 2014-02-27
EP2450057B1 (de) 2016-09-28
CL2008002417A1 (es) 2009-03-27
SI2450057T1 (sl) 2017-01-31
AU2008287388A1 (en) 2009-02-19
LT2450057T (lt) 2016-12-27
HRP20120350T1 (hr) 2012-05-31
IL203824A (en) 2017-04-30
AR119704A2 (es) 2022-01-05
CN101820758A (zh) 2010-09-01
CA2871864A1 (en) 2009-02-19
TWI419899B (zh) 2013-12-21
US20120071684A1 (en) 2012-03-22
EP2187741B1 (de) 2012-03-14
CN103254267A (zh) 2013-08-21
EA018704B1 (ru) 2013-10-30
ES2382571T3 (es) 2012-06-11
US20090048204A1 (en) 2009-02-19
AU2008287388B2 (en) 2014-11-06
JP2010536754A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
BRPI0815540A2 (pt) Formas de éster metílico de cddo
DE502007000290D1 (de) Neue Verwendungen von Nonenolid
EP2217064A4 (de) Neue impfstoffe gegen mehrere subtypen des influenzavirus
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
DE602007003343D1 (de) Neue mikrobiozide
EP3064512C0 (de) Antikörper gegen cldn6
BRPI0908481A2 (pt) Aparelho de acabamento de concreto
DE602007010054D1 (de) Reparatur von Verbundwerkstoffen
BRPI0908796A2 (pt) Mangueira com expansão controladora
DE602007010966D1 (de) Neue Hautklammern
EP2030015A4 (de) Neugestaltung von proteinoberflächen
ATE513547T1 (de) Neue verfahren
EP2349335A4 (de) Levetiracetam-immunoassays
EP2300038A4 (de) Verbesserte peptidmediatoren von cholesterinefflux
EP2255384A4 (de) Keramik-paddle
DE502007000436D1 (de) Neue Verwendungen von 4-Methyl-5-hydroxy-hexansäurelacton
FI20086002A0 (fi) Paneeli
FI20085807A0 (fi) Menetelmä essitalopraamin valmistamiseksi
BRPI0822288A2 (pt) tijolo perfurado
ATE524461T1 (de) Neue substituierte piperidylpropanthiole
EP2336311A4 (de) Antikörper gegen tuna vasa
ATE421572T1 (de) Neue stämme von lactobacillus helveticus
EP2142466A4 (de) Ultradünne magnesium-nanoblätter
ATE423840T1 (de) Neue stämme von lactobacillus helveticus
DE102007048335A8 (de) Neue Verwendung von If-Inhibitoren